Skip to main content
Erschienen in: CardioVascular and Interventional Radiology 1/2018

02.08.2017 | Clinical Investigation

Hepatic Arterial Embolization Using Cone Beam CT with Tumor Feeding Vessel Detection Software: Impact on Hepatocellular Carcinoma Response

verfasst von: F. H. Cornelis, A. Borgheresi, E. N. Petre, E. Santos, S. B. Solomon, K. Brown

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Dedicated tumor feeding vessel detection software (TFVDS) using cone beam CT has shown a higher sensitivity to detect tumor feeding vessels during hepatic arterial embolization (HAE) of hepatocellular carcinoma (HCC) compared to 2D imaging. Our primary hypothesis was that HCC tumors treated with HAE guided by a TFVDS would show more complete response (CR) than when treated with 2D imaging alone. Secondary analysis of the impact on X-ray exposure was performed.

Materials and Methods

Nineteen males and 8 females (median age: 69 year, 46–85) with 44 tumors (median size: 38 mm, 6–100) treated with selective HAE between January 2013 and December 2014 were included. Exclusion criteria were: extra-hepatic supply, >4 tumors, tumor size >10 cm, and adjunctive local therapy. Baseline patient and procedure characteristics were reviewed. Differences in CR per modified Response Evaluation Criteria in Solid Tumors were assessed by univariate and multivariate analyses for tumor size, number, location, particles size, and use of TFVDS.

Results

Median imaging follow-up was 20.1 months (2–33). Use of TFVDS (13 patients, 19 tumors) was the only factor predictive of CR (OR = 3.85 [CI95%: 1.09, 13.67], p = 0.04) on univariate analysis but not on multivariate analysis (OR = 3.26 [0.87, 12.23], p = 0.08). A higher rate of CR was observed for HAE using TFVDS guidance versus 2D imaging alone (68.4%, 13–19, vs. 36%, 9–25, p = 0.03). Median dose area product was lower when TFVDS was used (149.7 Gy.cm2, 38–365, vs. 227.8 Gy.cm2, 85.3–468.6, p = 0.05).

Conclusions

HCC embolized with TFVDS may result in improved local tumor response without increasing the dose exposure.
Literatur
1.
Zurück zum Zitat Mauri G, Varano GM, Orsi F. TAE for HCC: when the old way is better than the new ones!!! Cardiovasc Intervent Radiol. 2016;39(6):799–800.CrossRefPubMed Mauri G, Varano GM, Orsi F. TAE for HCC: when the old way is better than the new ones!!! Cardiovasc Intervent Radiol. 2016;39(6):799–800.CrossRefPubMed
2.
Zurück zum Zitat Bonomo G, Pedicini V, Monfardini L, et al. Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc Intervent Radiol. 2010;33(3):552–9.CrossRefPubMed Bonomo G, Pedicini V, Monfardini L, et al. Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc Intervent Radiol. 2010;33(3):552–9.CrossRefPubMed
3.
Zurück zum Zitat Bonomo G, Della Vigna P, Monfardini L, et al. Combined therapies for the treatment of technically unresectable liver malignancies: bland embolization and radiofrequency thermal ablation within the same session. Cardiovasc Intervent Radiol. 2012;35(6):1372–9.CrossRefPubMed Bonomo G, Della Vigna P, Monfardini L, et al. Combined therapies for the treatment of technically unresectable liver malignancies: bland embolization and radiofrequency thermal ablation within the same session. Cardiovasc Intervent Radiol. 2012;35(6):1372–9.CrossRefPubMed
4.
Zurück zum Zitat Racadio JM, Babic D, Homan R, et al. Live 3D guidance in the interventional radiology suite. AJR Am J Roentgenol. 2007;189(6):W357–64.CrossRefPubMed Racadio JM, Babic D, Homan R, et al. Live 3D guidance in the interventional radiology suite. AJR Am J Roentgenol. 2007;189(6):W357–64.CrossRefPubMed
5.
Zurück zum Zitat Iwazawa J, Ohue S, Hashimoto N, Muramoto O, Mitani T. Survival after C-arm CT-assisted chemoembolization of unresectable hepatocellular carcinoma. Eur J Radiol. 2012;81(12):3985–92.CrossRefPubMed Iwazawa J, Ohue S, Hashimoto N, Muramoto O, Mitani T. Survival after C-arm CT-assisted chemoembolization of unresectable hepatocellular carcinoma. Eur J Radiol. 2012;81(12):3985–92.CrossRefPubMed
6.
Zurück zum Zitat Ronot M, Abdel-Rehim M, Hakime A, et al. Cone-beam CT angiography for determination of tumor-feeding vessels during chemoembolization of liver tumors: comparison of conventional and dedicated-software analysis. J Vasc Interv Radiol. 2016;27(1):32–8.CrossRefPubMed Ronot M, Abdel-Rehim M, Hakime A, et al. Cone-beam CT angiography for determination of tumor-feeding vessels during chemoembolization of liver tumors: comparison of conventional and dedicated-software analysis. J Vasc Interv Radiol. 2016;27(1):32–8.CrossRefPubMed
7.
Zurück zum Zitat Tacher V, Radaelli A, Lin M, Geschwind JF. How I do it: cone-beam CT during transarterial chemoembolization for liver cancer. Radiology. 2015;274(2):320–34.CrossRefPubMedPubMedCentral Tacher V, Radaelli A, Lin M, Geschwind JF. How I do it: cone-beam CT during transarterial chemoembolization for liver cancer. Radiology. 2015;274(2):320–34.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Pellerin O, Lin M, Bhagat N, Shao W, Geschwind JF. Can C-arm cone-beam CT detect a micro-embolic effect after TheraSphere radioembolization of neuroendocrine and carcinoid liver metastasis? Cancer Biother Radiopharm. 2013;28(6):459–65.CrossRefPubMedPubMedCentral Pellerin O, Lin M, Bhagat N, Shao W, Geschwind JF. Can C-arm cone-beam CT detect a micro-embolic effect after TheraSphere radioembolization of neuroendocrine and carcinoid liver metastasis? Cancer Biother Radiopharm. 2013;28(6):459–65.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Bapst B, Lagadec M, Breguet R, Vilgrain V, Ronot M. Cone beam computed tomography (CBCT) in the field of interventional oncology of the liver. Cardiovasc Intervent Radiol. 2016;39(1):8–20.CrossRefPubMed Bapst B, Lagadec M, Breguet R, Vilgrain V, Ronot M. Cone beam computed tomography (CBCT) in the field of interventional oncology of the liver. Cardiovasc Intervent Radiol. 2016;39(1):8–20.CrossRefPubMed
10.
Zurück zum Zitat Deschamps F, Solomon SB, Thornton RH, et al. Computed analysis of three-dimensional cone-beam computed tomography angiography for determination of tumor-feeding vessels during chemoembolization of liver tumor: a pilot study. Cardiovasc Intervent Radiol. 2010;33(6):1235–42.CrossRefPubMedPubMedCentral Deschamps F, Solomon SB, Thornton RH, et al. Computed analysis of three-dimensional cone-beam computed tomography angiography for determination of tumor-feeding vessels during chemoembolization of liver tumor: a pilot study. Cardiovasc Intervent Radiol. 2010;33(6):1235–42.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Iwazawa J, Ohue S, Hashimoto N, Mitani T. Comparison of the number of image acquisitions and procedural time required for transarterial chemoembolization of hepatocellular carcinoma with and without tumor-feeder detection software. Radiol Res Pract. 2013;2013:580839.PubMedPubMedCentral Iwazawa J, Ohue S, Hashimoto N, Mitani T. Comparison of the number of image acquisitions and procedural time required for transarterial chemoembolization of hepatocellular carcinoma with and without tumor-feeder detection software. Radiol Res Pract. 2013;2013:580839.PubMedPubMedCentral
12.
Zurück zum Zitat European Association for the Study of the Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer (Oxford, England: 1990). 2012;48(5):599–641. European Association for the Study of the Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer (Oxford, England: 1990). 2012;48(5):599–641.
13.
Zurück zum Zitat Brown KT, Do RK, Gonen M, et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(17):2046–53.CrossRef Brown KT, Do RK, Gonen M, et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(17):2046–53.CrossRef
14.
Zurück zum Zitat Facciorusso A, Bellanti F, Villani R, et al. Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: a meta-analysis of randomized trials. United Eur Gastroenterol J. 2017;5(4):511–8.CrossRef Facciorusso A, Bellanti F, Villani R, et al. Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: a meta-analysis of randomized trials. United Eur Gastroenterol J. 2017;5(4):511–8.CrossRef
15.
Zurück zum Zitat Massarweh NN, Davila JA, El-Serag HB, et al. Transarterial bland versus chemoembolization for hepatocellular carcinoma: rethinking a gold standard. J Surg Res. 2016;200(2):552–9.CrossRefPubMed Massarweh NN, Davila JA, El-Serag HB, et al. Transarterial bland versus chemoembolization for hepatocellular carcinoma: rethinking a gold standard. J Surg Res. 2016;200(2):552–9.CrossRefPubMed
16.
Zurück zum Zitat Wang X, Erinjeri JP, Jia X, et al. Pattern of retained contrast on immediate postprocedure computed tomography (CT) after particle embolization of liver tumors predicts subsequent treatment response. Cardiovasc Intervent Radiol. 2013;36(4):1030–8.CrossRefPubMed Wang X, Erinjeri JP, Jia X, et al. Pattern of retained contrast on immediate postprocedure computed tomography (CT) after particle embolization of liver tumors predicts subsequent treatment response. Cardiovasc Intervent Radiol. 2013;36(4):1030–8.CrossRefPubMed
17.
Zurück zum Zitat Jung E, Kim J, Yoon E, et al. The optimal tumor response assessment in patients with HCC after treatment of TACE. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(4_suppl):215.CrossRef Jung E, Kim J, Yoon E, et al. The optimal tumor response assessment in patients with HCC after treatment of TACE. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(4_suppl):215.CrossRef
18.
Zurück zum Zitat Kothary N, Takehana C, Mueller K, et al. watershed hepatocellular carcinomas: the risk of incomplete response following transhepatic arterial chemoembolization. J Vasc Interv Radiol. 2015;26(8):1122–9.CrossRefPubMed Kothary N, Takehana C, Mueller K, et al. watershed hepatocellular carcinomas: the risk of incomplete response following transhepatic arterial chemoembolization. J Vasc Interv Radiol. 2015;26(8):1122–9.CrossRefPubMed
19.
Zurück zum Zitat Vincenzi B, Di Maio M, Silletta M, et al. Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a literature-based meta-analysis. PLoS ONE. 2015;10(7):e0133488.CrossRefPubMedPubMedCentral Vincenzi B, Di Maio M, Silletta M, et al. Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a literature-based meta-analysis. PLoS ONE. 2015;10(7):e0133488.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Basile A, Carrafiello G, Ierardi A, Tsetis D, Brountzos E. Quality-improvement guidelines for hepatic transarterial chemoembolization. Cardiovasc Intervent Radiol. 2012;35:765–74.CrossRefPubMed Basile A, Carrafiello G, Ierardi A, Tsetis D, Brountzos E. Quality-improvement guidelines for hepatic transarterial chemoembolization. Cardiovasc Intervent Radiol. 2012;35:765–74.CrossRefPubMed
21.
Zurück zum Zitat Miyayama S, Yamashiro M, Hashimoto M, et al. Identification of small hepatocellular carcinoma and tumor-feeding branches with cone-beam CT guidance technology during transcatheter arterial chemoembolization. J Vasc Interv Radiol. 2013;24(4):501–8.CrossRefPubMed Miyayama S, Yamashiro M, Hashimoto M, et al. Identification of small hepatocellular carcinoma and tumor-feeding branches with cone-beam CT guidance technology during transcatheter arterial chemoembolization. J Vasc Interv Radiol. 2013;24(4):501–8.CrossRefPubMed
22.
Zurück zum Zitat Minami Y, Yagyu Y, Murakami T, Kudo M. Tracking navigation imaging of transcatheter arterial chemoembolization for hepatocellular carcinoma using three-dimensional cone-beam CT angiography. Liver Cancer. 2014;3(1):53–61.CrossRefPubMedPubMedCentral Minami Y, Yagyu Y, Murakami T, Kudo M. Tracking navigation imaging of transcatheter arterial chemoembolization for hepatocellular carcinoma using three-dimensional cone-beam CT angiography. Liver Cancer. 2014;3(1):53–61.CrossRefPubMedPubMedCentral
Metadaten
Titel
Hepatic Arterial Embolization Using Cone Beam CT with Tumor Feeding Vessel Detection Software: Impact on Hepatocellular Carcinoma Response
verfasst von
F. H. Cornelis
A. Borgheresi
E. N. Petre
E. Santos
S. B. Solomon
K. Brown
Publikationsdatum
02.08.2017
Verlag
Springer US
Erschienen in
CardioVascular and Interventional Radiology / Ausgabe 1/2018
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-017-1758-2

Weitere Artikel der Ausgabe 1/2018

CardioVascular and Interventional Radiology 1/2018 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.